Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index; 4 of the 15 sources its claims cite were checked for support.
Abstract
The nuclear-encoded Krebs cycle enzymes, fumarate hydratase (FH) and succinate dehydrogenase (SDHB, -C and -D), act as tumour suppressors. Germline mutations in FH predispose individuals to leiomyomas and renal cell cancer (HLRCC), whereas mutations in SDH cause paragangliomas and phaeochromocytomas (HPGL). In this study, we have shown that FH-deficient cells and tumours accumulate fumarate and, to a lesser extent, succinate. SDH-deficient tumours principally accumulate succinate. In situ analyses showed that these tumours also have over-expression of hypoxia-inducible factor 1alpha (HIF1alpha), activation of HIF1alphatargets (such as vascular endothelial growth factor) and high microvessel density. We found no evidence of increased reactive oxygen species in our cells. Our data provide in vivo evidence to support the hypothesis that increased succinate and/or fumarate causes stabilization of HIF1alpha a plausible mechanism, inhibition of HIF prolyl hydroxylases, has previously been suggested by in vitro studies. The basic mechanism of tumorigenesis in HPGL and HLRCC is likely to be pseudo-hypoxic drive, just as it is in von Hippel-Lindau syndrome.
Overview
CoChat Summary
TL;DR
This study provides in vivo evidence that germline FH and SDH mutations lead to accumulation of Krebs cycle intermediates and HIF1α over-expression in HLRCC and HPGL tumours, supporting pseudo-hypoxic drive as a shared tumorigenic mechanism. It also finds no evidence of increased reactive oxygen species in FH-deficient cells.
Key findings
- FH-deficient fibroblasts and HLRCC fibroids accumulate fumarate and succinate. FH-deficient fibroblast succinate was mean 59.4 mmol/g protein (median 39.8, range 32–125.9) versus controls mean 17.4 (median 14.5, range 9.9–29.8); HLRCC fibroids had succinate 70–98 and fumarate 417–688 mmol/g protein, with succinate:fumarate ratios of 0.10–0.22 versus >1 in myometria.
- SDH-deficient HPGL tumours principally accumulate succinate. SDHB-mutant paragangliomas had succinate 364.5 and 517.0 mmol/g protein versus non-HPGL tumours 32.3–49.7; one SDHB tumour (patient 4) did not show elevated succinate.
- HIF1α over-expression and HIF-target activation were seen in tumours: strong nuclear HIF1α in all HPGL tumours studied (12 paragangliomas and 4 phaeochromocytomas), moderate staining in HLRCC fibroids, and very strong staining in three renal cancers; VEGF expression was high and CD34 showed high microvessel density. Western blotting confirmed a 120 kDa HIF1α band only in tumour, not normal kidney.
- No notable increase in oxidative stress was found: SOD mean was 44.4 versus 38.2 mU/mg and reduced glutathione mean was 5.52 versus 4.04 nmol/mg in FH-deficient versus control cells, with retained mitochondrial complex I, II–III and IV activities.
Methods
- Metabolomic profiling used 1H MRS on skin fibroblasts from four fumarase deficiency patients and six controls, and GC/MS on frozen HLRCC fibroids, myometrium controls, and frozen paragangliomas plus non-HPGL controls.
- Mutation screening of SDHB, SDHC and SDHD was performed by direct sequencing, with array CGH for allelic loss; tumour analyses included HIF1α and CD34 immunohistochemistry, VEGF in situ hybridization, and HIF1α western blotting.
- Samples included HLRCC fibroids and renal cancers, HPGL paragangliomas and phaeochromocytomas, and normal myometrium/kidney controls, all collected with Research Ethics Committee approval.
Limitations
- The paper states that formal statistical analysis was problematic given the small number of samples and lack of information on underlying factors; tumour scarcity also meant duplicate metabolite analysis was not possible.
- The paper notes that one SDHB tumour failed to show elevated succinate for unclear reasons, that HPGL versus other tumour succinate differences were only just significant (P = 0.045) owing to sample 3, and that direct PHD inhibition by fumarate in HLRCC cannot be excluded.
- Evident from the text: HIF1α staining was also weak/moderate in surrounding myometrium, and the oxidative-stress conclusion rests on only two FH-deficient lines for SOD/glutathione assays.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 7 Not checked · 67 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“germline mutations in the B, C and D subunits of SDH predispose individuals to hereditary paragangliomatosis with phaeochromocytomas (HPGL) (2 -6)”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > INTRODUCTION
What the sources say
- Not checked yetcites [2] Baysal, B.E., Ferrell, R.E., Willett-Brozick, J.E., Lawrence, E.C., Myssiorek, D., Bosch, A., van der Mey, A., Taschner, P.E., Rubinstein, W.S., Myers, E.N. et al. (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 287, 848-851. source
- Not checked yetcites [3] Gimm, O., Armanios, M., Dziema, H., Neumann, H.P. and Eng, C. (2000) Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res., 60, 6822-6825.
- Not checked yetcites [4] Niemann, S. and Muller, U. (2000) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet., 26, 268-270. source
- Partly supportedcites [5] Astuti, D., Latif, F., Dallol, A., Dahia, P.L., Douglas, F., George, E., Skoldberg, F., Husebye, E.S., Eng, C. and Maher, E.R. (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet., 69, 49-54. sourceExperimental — accuracy not yet measured
The Abstract and Results of Astuti et al. (2001) support the SDHB component strongly: inactivating germline SDHB mutations were found in eight families 'segregating pheochromocytoma with or without head and neck paraganglioma' plus one occult germline case, and the SDHD association is stated as background ('pheochromocytoma susceptibility has been associated with germline SDHD mutations'). The SDHC component is not this paper's finding: the Results state 'No pathogenic mutations were identified in SDHC' and 'there was no evidence of germline SDHC mutations in the kindreds with familial pheochromocytoma and paraganglioma', with the SDHC link credited to Niemann and Muller (2000) in the Discussion, and the Abstract hedges that SDHC and SDHD mutations 'may cause hereditary paraganglioma'. So the composite claim (B, C and D, stated as established predisposition) overstates what this source reports for SDHC. (LLM, conf=0.78)
- Not checked yetcites [6] Astuti, D., Douglas, F., Lennard, T.W., Aligianis, I.A., Woodward, E.R., Evans, D.G., Eng, C., Latif, F. and Maher, E.R. (2001) Germline SDHD mutation in familial phaeochromocytoma. Lancet, 357, 1181-1182. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“neither our data nor those of Selak et al. (27) have provided evidence for an alternative model of tumorigenesis in HLRCC or HPGL based on increased levels of ROSs.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Partly supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. sourceExperimental — accuracy not yet measured
In “Reactive oxygen species do not play a role in HIF-1α induction after SDH inhibition” (page not available), Selak et al. report no detectable increase in ROS or change in glutathione redox state after SDH inhibition. That supports the statement as applied to the SDH-related HPGL model, but these data do not test the FH-related HLRCC model. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Selak et al. (27) showed that the mechanism for these findings may be inhibition by succinate of HIF PHDs, which rely for their activity on conversion of a-ketoglutarate to succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. source
The Introduction states that HIF prolyl hydroxylases use α-ketoglutarate and convert it to succinate during hydroxylation. In “Succinate is accumulated in SDH-inhibited cells,” the authors propose that accumulated succinate may inhibit this required reaction and impede PHD activity. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Selak et al. (27) tested a model of tumorigenesis in which raised levels of succinate caused increased HIF1a expression in vitro.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. source
In the section on succinate elevation and HIF-1α stabilization in cells (page unavailable), Selak et al. report that cells treated with a membrane-permeable succinate derivative had elevated HIF-1α levels under normoxic conditions. This supports the attributed in-vitro model; the measured increase was in HIF-1α protein levels, through stabilization. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“FH-deficient cells and tumours accumulate fumarate and, to a lesser extent, succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 78 claims and to verify the 11 references still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 14
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevation of fumarate and succinate, such as in renal cancer subtypes bearing succinate dehydrogenase (SDH) or fumarate hydratase mutations, suppress HIF-α hydroxylation by the PHDs, resulting in the stabilization of both HIF-1α and HIF-2α [20].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, unlike pVHL-deficient ccRCC tumors that constitutively express both HIF isoforms or HIF-2α preferentially, renal cancers bearing FH/SDH mutations tend to preferentially express HIF-1α [20].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, succinate and fumarate inhibit the prolyl hydroxylase domain-containing (PHD) enzymes that regulate stability of hypoxia-inducible factors (HIFs), such that FH and SDH deficient cancers activate the hypoxic gene expression program even under normoxic conditions (Hewitson et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Pollard et al., 2005
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To date, the clearest evidence that metabolites modulate HIF signaling comes from cells that are genetically defective in fumarate hydratase (FH) (Isaacs et al., 2005) or succinate hydrogenase (SDH; subunits b, c, and d) (MacKenzie et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Pollard et al., 2005
In the citing paper
“For example, the increase in ROS induced by antimycin A can be abolished by adding either stigmatellin or myxothiazol (256).”
From Mitochondrial reactive oxygen species production in excitable cells: Modulators of mitochondrial and cell function (2009) · cites this paper as [256]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Increased succinate in HPGL tumours
“One SDHB tumour (patient 4) did not show elevated succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Western blotting
“| 4 | No | 32.3 | 3.0 | 10.8 |”
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 1×
“Mutations in VHL cause stabilization of the subunits of hypoxia-inducible factor (HIF) (18), which initiates the transcription of genes coding for pro-angiogenic proteins such as VEGF (19).”
BackgroundSuccinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108 · cited 4×
“Recently, support has been provided using an in vitro system for dysfunction of the Krebs cycle leading to the stabilization of HIF (27).”
BackgroundInfluentialMutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
Self-citationTransition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383 · cited 1×
“Oxidative stress in FH-deficient and control cells was measured using a HPLC method to analyse the oxidation status of the antioxidant glutathione as previously described (33).”
Method[45] Cytochrome oxidase from beef heart mitochondria
Wharton, D. C., & Tzagoloff, A. (1967) · Methods in Enzymology · doi:10.1016/0076-6879(67)10048-7 · Cited by 1,261
Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087
Architecture of succinate dehydrogenase and reactive oxygen species generation
Yankovskaya, V., Horsefield, R., Törnroth, S., Luna-Chavez, C., Miyoshi, H., Léger, C., Byrne, B., Cecchini, G., & Iwata, S. (2003) · Science · doi:10.1126/science.1079605 · Cited by 927
Neumann, H. P. H. (2004) · JAMA · doi:10.1001/jama.292.8.943 · Cited by 893 · cited 1×
“SDHB mutations are associated with a higher proportion of malignant lesions and a relatively greater risk of phaeochromocytoma (8).”
Background
Cited by
Items 301–400 of 982
Evolving concepts in pheochromocytoma and paraganglioma
Dahia, P. L. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000198017.45982.06 · Cited by 69
Yap, Z. Y., Strucinska, K., Matsuzaki, S., Lee, S., Si, Y. C., Humphries, K. M., Tarnopolsky, M. A., & Yoon, W. H. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12248 · Cited by 71
Hypoxic Regulation of Gene Transcription and Chromatin: Cause and Effect
Kindrick, J. D., & Mole, D. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218320 · Cited by 72
New Insights into the Biology of Renal Cell Carcinoma
Li, L., & Kaelin, W. G. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.04.004 · Cited by 71
Exploiting Mitochondrial Dysfunction for Effective Elimination of Imatinib-Resistant Leukemic Cells
Kluza, J., Jendoubi, M., Ballot, C., Dammak, A., Jonneaux, A., Idziorek, T., Joha, S., Dauphin, V., Malet‐Martino, M., Balayssac, S., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021924 · Cited by 71
“Accumulation of succinate and fumarate in cancer cells induces inhibition of HIF prolyl hydroxylases allowing the nuclear translocation of HIF-1a [40].”
BackgroundOxygen regulation of TET enzymes
Matulevičiūtė, R., Cunha, P. P., Johnson, R. S., & Foskolou, I. P. (2021) · FEBS Journal · doi:10.1111/febs.15695 · Cited by 71
HIF and fumarate hydratase in renal cancer
Sudarshan, S., Linehan, W. M., & Neckers, L. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603547 · Cited by 71
“Although these studies focus on the effects of an acute change in SDH activity, paragangliomas from patients with germline SDHB mutations have been shown to have chronically elevated levels of succinate (Pollard et al, 2005b).”
BackgroundResultInfluentialEpidemiology, Aetiology, and Pathogenesis of Renal Cell Carcinoma
Protzel, C., Maruschke, M., & Hakenberg, O. W. (2012) · European Urology Supplements · doi:10.1016/j.eursup.2012.05.002 · Cited by 71
“Due to derangement of the mitochondrial conversion of fumarate to malate, fumarate is overaccumulated, and hypoxia leads to upregulation of HIF [36,41].”
BackgroundInfluentialHousley, S. L., Lindsay, R. S., Young, B., McConachie, M., Mechan, D., Baty, D. U., Christie, L., Rahilly, M., Qureshi, K. N., & Fleming, S. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03482.x · Cited by 70
Hereditary Renal Cell Carcinoma Syndromes: Clinical, Pathologic, and Genetic Features
Adeniran, A., Shuch, B. M., & Humphrey, P. A. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000562 · Cited by 70
Pheochromocytoma: The First Metabolic Endocrine Cancer
Jochmanová, I., & Pacák, K. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0606 · Cited by 70
Metabolic implications of hypoxia and pseudohypoxia in pheochromocytoma and paraganglioma
Kľučková, K., & Tennant, D. A. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2801-6 · Cited by 70
“…in tumour samples from PPGL patients have been confirmed in a number of studies (Imperiale et al. 2015; Lehtonen et al. 2007; Lendvai et al. 2014; Pollard et al. 2005; Richter et al. 2014) and high succinate to fumarate ratios suggested as a metabolic marker for the detection of SDHB/…”
BackgroundResultInfluentialFumarate Hydratase Deletion in Pancreatic β Cells Leads to Progressive Diabetes
Adam, J., Ramracheya, R., Chibalina, M. V., Ternette, N., Hamilton, A., Tarasov, A. I., Zhang, Q., Rebelato, E., Rorsman, N. J. G., Martín-del-Río, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.093 · Cited by 61
“…We generated animals in which Fh1 was deleted specifically in pancreatic b cells (Fh1fl/flRip2-Cre+/ ; Fh1bKO mice) by intercrossing an Fh1 conditional knockout mouse (Pollard et al., 2007) withmice expressing Cre recombinase driven by the rat insulin promoter (Rip2-Cre mice; Herrera, 2000).”
Self-citationHIF, a missing link between metabolism and cancer
Esteban, M. A., & Maxwell, P. H. (2005) · Nature Medicine · doi:10.1038/nm1005-1047 · Cited by 69
Fan, J., Kamphorst, J. J., Rabinowitz, J. D., & Shlomi, T. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.502740 · Cited by 67
Lalève, A., Fillinger, S., & Walker, A. (2014) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2014.03.006 · Cited by 68
Rao, J. U., Engelke, U. F. H., Rodenburg, R. J., Wevers, R. A., Pacák, K., Eisenhofer, G., Qin, N., Küsters, B., Goudswaard, A. G., Lenders, J. W. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3922 · Cited by 67
Insights into the Pathogenesis and Treatment of Cancer from Inborn Errors of Metabolism
Erez, A., Shchelochkov, O. A., Plon, S. E., Scaglia, F., & Lee, B. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.03.005 · Cited by 67
“Multiple studies show that severe accumulation of succinate and fumarate cause a pseudohypoxia state resulting in an inhibition of hypoxia-inducible factor (HIF) hydroxylases and leading to stabilization of activated HIF-1a and expression of HIF target proteins such as vascular endothelial growth factor (VEGF).(113) H…”
BackgroundLi, J., Liang, N. N., Long, X., Zhao, J., Yang, J., Du, X., Yang, T., Yuan, P., Huang, X., Zhang, J., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.07.001 · Cited by 67
Metabolic Reprogramming in Cancer: Implications for Immunosuppressive Microenvironment
Aden, D., Sureka, N., Zaheer, S., Chaurasia, J. K., & Zaheer, S. (2024) · Immunology · doi:10.1111/imm.13871 · Cited by 67
Past, Present, and Future of Molecular and Cellular Oncology
Galluzzi, L., Vitale, I., & Kroemer, G. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00001 · Cited by 66
Shanmugasundaram, K., Nayak, B., Shim, E., Livi, C. B., Block, K. L., & Sudarshan, S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.568162 · Cited by 66
Citric Acid Cycle Intermediates in Cardioprotection
Czibik, G., Steeples, V., Yavari, A., & Ashrafian, H. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.114.000220 · Cited by 67
IDH Mutations in Tumorigenesis and Their Potential Role As Novel Therapeutic Targets
Krell, D., Mulholland, P. J., Frampton, A. E., Krell, J., Stebbing, J., & Bardella, C. (2013) · Future Oncology · doi:10.2217/fon.13.143 · Cited by 68
Laukka, T., Myllykoski, M., Looper, R. E., & Koivunen, P. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.048 · Cited by 61
Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options
Nölting, S., Grossman, A. B., & Pacák, K. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0715-1888 · Cited by 67
“On the other hand, another study [31, 32] found more frequent HIF-2α overexpression in VHL-mutated PCCs and PGLs, whereas in SDH-related tumours nuclear HIF-1α staining was more prominent, although these findings in a single study are controversial.”
The Evolving Field of Tyrosine Kinase Inhibitors in the Treatment of Endocrine Tumors
Ye, L., Santarpia, L., & Gagel, R. F. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0031 · Cited by 65
Mitochondrial Dysfunction Impairs Tumor Suppressor p53 Expression/Function
Compton, S. L., Kim, C. G., Griner, N. B., Potluri, P., Scheffler, I. E., Sen, S., Jerry, D. J., Schneider, S. S., & Yadava, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.163063 · Cited by 66
Sudarshan, S., Pinto, P. A., Neckers, L., & Linehan, W. M. (2007) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0711 · Cited by 65
“demonstrated (by immunochemistry and immunoblotting) that there was strong HIF-1 expression in kidney tumors from HLRCC patients”
BackgroundSzeto, S. S. W., Reinke, S. N., Sykes, B. D., & Lemire, B. D. (2010) · Journal of Proteome Research · doi:10.1021/pr100880y · Cited by 65
The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation
Acuña-Pilarte, K., & Koh, M. Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.06.005 · Cited by 64
Alston, C. L., Berti, C. C., Blakely, E. L., Oláhová, M., He, L., McMahon, C. J., Olpin, S. E., Hargreaves, I. P., Nolli, C., McFarland, R., et al. (2015) · Human Genetics · doi:10.1007/s00439-015-1568-z · Cited by 64
“This in turn creates a pseudo-hypoxic state, prompting a switch to glycolytic respiration consistent with neoplasia (Hanahan and Weinberg 2011; Pollard et al. 2005).”
BackgroundSelf-citationOncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype
Cuyàs, E., Fernández-Arroyo, S., Corominas-Faja, B., Rodríguez-Gallego, E., Bosch-Barrera, J., Martin-Castillo, B., De Llorens, R., Joven, J., & Menendez, J. A. (2015) · Oncotarget · doi:10.18632/oncotarget.3733 · Cited by 58
“FH- and SDH-deficient cells and tumors exhibit activation of hypoxia-inducible factoralpha (HIFα) under normoxia, termed pseudohypoxia, which can be attributed to the allosteric inhibition of HIFα-prolyl hydroxylases by the accumulation of fumarate and succinate, respectively [15-22].”
BackgroundBaysal, B. E., & Maher, E. R. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0226 · Cited by 64
“Accordingly, the knockdown of FH in cell lines led to robust stabilizationofHIF1a through fumarate mediated inhibition of the PhD enzymes (Isaacs et al. 2005).”
BackgroundInfluentialZeng, L., Wang, Y., Ai, C., Zheng, J., Wu, C., & Cai, R. (2016) · Fish Physiology and Biochemistry · doi:10.1007/s10695-016-0227-1 · Cited by 64
Willmann, L., Schlimpert, M., Halbach, S., Erbes, T., Stickeler, E., & Kammerer, B. (2015) · Journal of Chromatography B · doi:10.1016/j.jchromb.2015.07.021 · Cited by 64
Chemically induced pheochromocytomas in rats: mechanisms and relevance for human risk assessment
Greim, H. A., Hartwig, A., Reuter, U., Richter-Reichhelm, H.-B., & Thielmann, H. W. (2009) · Critical Reviews in Toxicology · doi:10.1080/10408440903190861 · Cited by 63
“Hereditary defects in the fumarate hydratase gene are associated with leiomyomas and leiomyosarcomas of the uterus and the skin and with renal cell carcinomas (Pollard et al., 2003, 2005; Tomlinson et al., 2002; Toro et al., 2003).”
BackgroundCarney Triad, Carney-Stratakis Syndrome, 3PAS and Other Tumors Due to SDH Deficiency
Pitsava, G., Settas, N., Faucz, F. R., & Stratakis, C. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.680609 · Cited by 61
Succinate dehydrogenase-deficient gastrointestinal stromal tumors
Wang, Y., Gu, M.-L., & Ji, F. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i8.2303 · Cited by 61
Modulation of the Hypoxic Response
Pugh, C. W. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-1-4899-7678-9_18 · Cited by 61
Wenger, R. H., & Kurtz, A. (2011) · Comprehensive physiology · doi:10.1002/cphy.c100075 · Cited by 61
Scatena, R. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2869-1_15 · Cited by 60
Metabolic intermediates – Cellular messengers talking to chromatin modifiers
Nieborak, A., & Schneider, R. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.01.007 · Cited by 61
Fandrey, J., Schödel, J., Eckardt, K., Katschinski, D. M., & Wenger, R. H. (2019) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-019-02334-8 · Cited by 60
“Loss-offunction mutations of SDH and FH lead to the accumulation of succinate and fumarate, respectively, two known inhibitors of the PHD enzymes [101].”
BackgroundEpigenomic and enhancer dysregulation in uterine leiomyomas
Mlodawska, O. W., Saini, P., Parker, J. B., Wei, J., Bulun, S. E., Simon, M. A., & Chakravarti, D. (2022) · Human Reproduction Update · doi:10.1093/humupd/dmac008 · Cited by 60
Gaster, M., Nehlin, J. O., & Minet, A. D. (2012) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2012.656653 · Cited by 63
Selak, M. A., Durán, R. V., & Gottlieb, E. (2006) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2006.05.015 · Cited by 59
Wentzel, J. F., Lewies, A., Bronkhorst, A. J., van Dyk, E., Plessis, D., & Pretorius, P. J. (2017) · Biochimie · doi:10.1016/j.biochi.2017.01.004 · Cited by 59
Immunometabolism: A new target for improving cancer immunotherapy
Guo, C., Chen, S., Liu, W., Ma, Y., Li, J., Fisher, P. B., Fang, X., & Wang, X. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.004 · Cited by 59
“Tumor cells also undergo glycolysis when cultured in vitro under normoxic conditions (Maxwell et al., 1999; Pollard et al., 2005).”
BackgroundSuccinate Dehydrogenase Loss in Familial Paraganglioma: Biochemistry, Genetics, and Epigenetics
Her, Y. F., & Maher, L. J. (2015) · International Journal of Endocrinology · doi:10.1155/2015/296167 · Cited by 58
Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC
Yamasaki, T., Tran, T. A. T., Öz, O. K., Raj, G. V., Schwarz, R. E., DeBerardinis, R. J., Zhang, X., & Brugarolas, J. (2011) · Nature Reviews Urology · doi:10.1038/nrurol.2010.234 · Cited by 58
Si, R.-W., Zhai, D.-D., Liao, Z.-H., Gao, L., & Yong, Y. (2014) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.12.035 · Cited by 58
Houston, M. A., Augenlicht, L. H., & Heerdt, B. G. (2011) · International Journal of Cell Biology · doi:10.1155/2011/978583 · Cited by 60
Metabolic interactions with cancer epigenetics
Gao, X., Reid, M. A., Kong, M., & Locasale, J. W. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.09.001 · Cited by 56
Hypoxic Signalling in Tumour Stroma
Laitala, A., & Erler, J. T. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00189 · Cited by 58
Fumarase: From the TCA Cycle to DNA Damage Response and Tumor Suppression
Leshets, M., Silas, Y., Lehming, N., & Pines, O. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00068 · Cited by 59
“At this stage, the fumarate concentration in the single tumor cell may not be sufficient for HIF stabilization.”
BackgroundInfluentialSkala, S. L., Dhanasekaran, S. M., & Mehra, R. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0216-ra · Cited by 58
“Competitive inhibition of prolylhydroxylase domain-containing proteins ultimately affects the stability of proteins such as the transcription factor hypoxia-induced factor 1 (HIF1).(49,50) Such events lead to succinylation of several proteins, including KEAP1, a component of the cullin 3 E3 ubiquitin ligase, thereby d…”
BackgroundFrom Nf1 to Sdhb knockout: Successes and failures in the quest for animal models of pheochromocytoma
Lussey‐Lepoutre, C., Thibault, C., Buffet, A., Morin, A., Badoual, C., Bénit, P., Rustin, P., Ottolenghi, C., Janin, M., Castro‐Vega, L. J., et al. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.027 · Cited by 58
“In contrast with human PPGL (Pollard et al., 2005), no accumulation of succinate was detected in any of these tumors (Fig.”
Self-citationHypoxia-inducible factors and cancer
Calzada, M. J., & del Peso, L. (2007) · Clinical & Translational Oncology · doi:10.1007/s12094-007-0055-y · Cited by 59
“mutation of citric acid cycle enzymes [136].”
BackgroundTomitsuka, E., Kita, K., & Esumi, H. (2009) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.85.258 · Cited by 57
Decoding Warburg's hypothesis: tumor-related mutations in the mitochondrial respiratory chain
García-Heredia, J. M., & Carnero, A. (2015) · Oncotarget · doi:10.18632/oncotarget.6057 · Cited by 59
“Thus, an activated HIF-a pathway has been detected in SDH-deficient tumors [80, 83, 84].”
BackgroundMetabolic Rewiring and the Characterization of Oncometabolites
Beyoğlu, D., & Idle, J. R. (2021) · Cancers · doi:10.3390/cancers13122900 · Cited by 58
“Targeted GC–MS metabolomics was also employed to analyze TCA cycle metabolites in HLRCC and other tumor samples [45].”
MethodFerroptosis: Mechanism and connections with cutaneous diseases
Liu, L., Lian, N., Shi, L., Hao, Z., & Chen, K. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1079548 · Cited by 56
“Reduced FH enzyme activity leads to the accumulation of the cellular level of fumarate, and fumarate can undergo a reaction with cysteine residues of proteins, which is called succination (Blatnik et al., 2008; Pollard et al., 2005).”
BackgroundPithukpakorn, M., Wei, M.-H., Toure, O., Steinbach, P. J., Glenn, G. M., Zbar, B., Linehan, W. M., & Toro, J. R. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2006.041087 · Cited by 56
Metabolic Cancer-Macrophage Crosstalk in the Tumor Microenvironment
de Goede, K. E., Driessen, A. J. M., & den Bossche, J. V. (2020) · Biology · doi:10.3390/biology9110380 · Cited by 56
“Immune inhibitory functions were also found in dendritic cells (DCs) [72] and microglia, where D-2HG inhibits activation by AMP-activated protein kinase (AMPK)-mediated downregulation of mTOR and downstream nuclear factor κB (NF-κB)-induced inflammatory responses [73].”
BackgroundInfluentialDahia, P. L. M. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.023 · Cited by 56
Castro, B. D., Pintado, C. O., García‐Flores, P., López‐Barneo, J., & Piruat, J. I. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00128-12 · Cited by 55
“stabilization and nuclear translocation in normoxia (8, 41, 51).”
BackgroundThe role of PHD2 mutations in the pathogenesis of erythrocytosis
Gardie, B., Percy, M. J., Hoogewijs, D., Chowdhury, R., Bento, C., McMullin, M. F., Schofield, C. J., Lee, F. S., Richard, S., Arsenault, P. R., et al. (2014) · Hypoxia · doi:10.2147/hp.s54455 · Cited by 55
Owens, K. M., Aykin-Burns, N., Dayal, D., Coleman, M. C., Domann, F. E., & Spitz, D. R. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.435 · Cited by 52
Merlo, A., Fernández, S. B. D. Q., Secades, P., Zambrano, I., Balbín, M., Astudillo, A., Scola, B., Arístegui, M., Suarez, C. M., & Chiara, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2410 · Cited by 55
Obesity, Cholesterol, and Clear-Cell Renal Cell Carcinoma (RCC)
Drabkin, H. A., & Gemmill, R. M. (2010) · Advances in cancer research · doi:10.1016/s0065-230x(10)07002-8 · Cited by 56
Long, Y., Tsai, W.-B., Wang, D., Hawke, D. H., Savaraj, N., Feun, L. G., Hung, M., Chen, H. H. W., & Kuo, M. T. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.11.028 · Cited by 54
“RCC is characterized by fumarate accumulation and HIF-1α overexpression [39], because fumarate functions as a competitor of prolyl hydroxylase, an enzyme that hydroxylates HIF-1α for proteasome-mediated HIF-1α degradation [23].”
BackgroundSuccinate dehydrogenase subunit B inhibits the AMPK-HIF-1¿ pathway in human ovarian cancer in vitro
Chen, L., Liu, T., Zhang, S., Zhou, J., Wang, Y., & Di, W. J. (2014) · Journal of Ovarian Research · doi:10.1186/s13048-014-0115-1 · Cited by 56
“Immunohistochemical analysis shows strong staining of hypoxiainducible factor-1α (HIF-1α) and the angiogenic factor, vascular endothelial growth factor in a malignant sporadic pheochromocytoma caused by a germline missense mutation in the SDHB gene [13], suggesting that activation of the hypoxia-response pathway may b…”
BackgroundJose, C., Melser, S., Benard, G., & Rossignol, R. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4357 · Cited by 46
“Accordingly, increased levels of Hif1 a were associated with the accumulation of Krebs cycle intermediates (214).”
Egan, G., Khan, D. H., Lee, J. B., Mirali, S., Zhang, L., & Schimmer, A. D. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1227 · Cited by 54
“Likewise, germline mutations in succinate dehydrogenase lead to increased cellular levels of succinate (38) and are associated with the development of paragangliomas and pheochromocytomas (41, 42).”
BackgroundTargeted therapeutic strategies for the management of renal cell carcinoma
Singer, E. A., Gupta, G. N., & Srinivasan, R. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328351c646 · Cited by 52
“Loss of SDHB activity leads to accumulation of succinate and inhibition of prolyl hydroxylase activity with consequent stabilization of HIF and upregulation of its downstream transcriptional targets [53].”
BackgroundRole of succinate dehydrogenase deficiency and oncometabolites in gastrointestinal stromal tumors
Zhao, Y., Feng, F., Guo, Q., Wang, Y., & Zhao, R. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i34.5074 · Cited by 53
Marden, J. H., Fescemyer, H. W., Schilder, R. J., Doerfler, W. R., Vera, J. C., & Wheat, C. W. (2012) · Evolution · doi:10.1111/evo.12004 · Cited by 52
Womeldorff, M. R., Gillespie, D. L., & Jensen, R. L. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14496 · Cited by 53
Icard, P., Simula, L., Wu, Z., Berzan, D., Sogni, P., Dohan, A. J. J., Dautry, R., Coquerel, A., Lincet, H., Loi, M., et al. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100790 · Cited by 52
Elevated plasma succinate in PTEN, SDHB, and SDHD mutation–positive individuals
Hobert, J. A., Mester, J. L., Moline, J., & Eng, C. (2012) · Genetics in Medicine · doi:10.1038/gim.2011.63 · Cited by 51
Fumarate Hydratase Deficiency and Cancer: Activation of Hypoxia Signaling?
Ratcliffe, P. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.03.015 · Cited by 51
Cancer morphogenesis: role of mitochondrial failure.
Fosslien, E. (2008) · PubMed · Cited by 51
A New Specific Succinate-Glutamate Metabolomic Hallmark in Sdhx-Related Paragangliomas
Impériale, A., Moussallieh, F., Sebag, F. A., Brunaud, L., Barlier, A., Elbayed, K., Bachellier, P., Goichot, B., Pacák, K., Namer, I. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080539 · Cited by 50
“The accumulation of these oncometabolites inhibits 2-oxoglutarate (2OG)-dependent dioxygenases that include EglN (also called PHD) family members, methylcytosine dioxygenases and JmjC domain-containing histone demethylases, which induces both pseudohypoxic and hypermethylated phenotypes [7–10].”
BackgroundLeiomyoma Cutis: A Focused Review on Presentation, Management, and Association with Malignancy
Malik, K., Patel, P. S., Chen, J., & Khachemoune, A. (2015) · American Journal of Clinical Dermatology · doi:10.1007/s40257-015-0112-1 · Cited by 50
“Stabilization is the result of accumulated fumarate (because of non-functional FH), which directly inhibits prolyl hydroxylases (PHDs), and thus impedes HIF degradation by the oxygen-dependent proteasomal E3 ubiquitin ligase complex [66, 67].”
BackgroundLiesenfeld, D. B., Habermann, N., Tóth, R., Owen, R. W., Frei, E., Böhm, J., Schrotz‐King, P., Klika, K. D., & Ulrich, C. M. (2014) · Metabolomics · doi:10.1007/s11306-014-0758-3 · Cited by 50
Fieuw, A., Kumps, C., Schramm, A. R., Pattyn, F., Menten, B., Antonacci, F., Sudmant, P. H., Schulte, J. H., Roy, N. V., Vergult, S., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26317 · Cited by 50
Seo, A. N., Yoon, G., & Ro, J. Y. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000138 · Cited by 50
Piantadosi, C. A., & Suliman, H. B. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709741200 · Cited by 51
Fumaric aciduria: an overview and the first Brazilian case report
Allegri, G., Fernandes, M. J., Scalco, F. B., Correia, P., Simoni, R. E., Llerena, J. C., & de Oliveira, M. L. C. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9134-2 · Cited by 50
Lucas, J. E., Kung, H.-N., & Chi, J.-T. A. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000920 · Cited by 49
“since it encodes a protein that catalyzes the post-translational formation of 4-hydroxyproline of the proline residues of HIF-1α and targets it for degradation via the von Hippel-Lindau ubiquitylation complex. Additionally, fumarate hydratase (FH) encodes a protein that is an enzymatic component of the tricarboxylic a…”
BackgroundMitochondrial Alterations During Carcinogenesis
Wang, X., Peralta, S., & Moraes, C. T. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-407190-2.00004-6 · Cited by 50
Prolyl-hydroxylase 3: evolving roles for an ancient signaling protein
Domann, F. E., & Place (2013) · Hypoxia · doi:10.2147/hp.s50091 · Cited by 50
“Abbreviations: PHD, prolyl-4-hydroxylase; HiF, hypoxia-inducible transcription factor; pO 2 , partial pressure of oxygen. act through product inhibition of the active site of PHD. 11,13 Mutations in IDH, on the other hand, promote the abnormal production of (R)-2-hydroxyglutarate (2-HG).”
Charville, G. W., & Longacre, T. A. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000166 · Cited by 49
Oncometabolites in cancer aggressiveness and tumour repopulation
Dando, I., Pozza, E. D., Ambrosini, G., Torrens‐Mas, M., Butera, G., Mullappilly, N., Pacchiana, R., Palmieri, M., & Donadelli, M. (2019) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12513 · Cited by 50
Hydroxylase-dependent regulation of the NF-κB pathway
Scholz, C. C., & Taylor, C. T. (2013) · Biological Chemistry · doi:10.1515/hsz-2012-0338 · Cited by 48
Stubbs, C. J., Loenarz, C., Mecinović, J., Yeoh, K. K., Hindley, N., Liénard, B. M. R., Sobott, F., Schofield, C. J., & Flashman, E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900285r · Cited by 49
Hereditary and familial kidney cancer
Coleman, J., & Russo, P. (2009) · Current Opinion in Urology · doi:10.1097/mou.0b013e32832f0d40 · Cited by 48
Metabolic Drivers in Hereditary Cancer Syndromes
Sciacovelli, M., Schmidt, C., Maher, E. R., & Frezza, C. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033612 · Cited by 48
Zhou, W., Dosey, T. L., Biechele, T. L., Moon, R. T., Horwitz, M. S., & Ruohola‐Baker, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027460 · Cited by 48
“can affect HIF stabilization [6,7].”
Metadata
- Authors
- Pollard, P. J., Brière, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., Hargreaves, I. P., Heales, S. J., Chung, Y. L., Griffiths, J. R., Dalgleish, A., McGrath, J. A., Gleeson, M. J., Hodgson, S. V., Poulsom, R., Rustin, P., & Tomlinson, I. P. M.
- Affiliations
- St Thomas' Hospital (GB)
- Cancer Research UK (GB)
- Sheffield Children's Hospital (GB)
- University Hospital of Wales (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- St George's Hospital (GB)
- Guy's Hospital (GB)
- Inserm (FR)
- Corresponding author
- Pollard, P.J.
- ORCID
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-29
- Volume
- 14
- Issue
- 15
- Pages
- 2231-2239
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2136749294
- Cited by
- 865
- References
- 39
- Citations by year
- 2026: 28 · 2025: 26 · 2024: 15 · 2023: 29 · 2022: 37 · 2021: 48 · 2020: 37 · 2019: 56 · 2018: 48 · 2017: 34 · 2016: 47 · 2015: 58 · 2014: 52 · 2013: 55 · 2012: 48
- FWCI
- 12.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Human Molecular Genetics (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Funders
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- fumarate hydratase, succinate dehydrogenase, Krebs cycle intermediates, fumarate accumulation, succinate accumulation, HIF-1α stabilization, hereditary leiomyomatosis and renal cell carcinoma, paraganglioma, pheochromocytoma, leiomyoma, microvessel density, vascular endothelial growth factor, reactive oxygen species
- MeSH terms
- Carcinoma, Renal Cell, Citric Acid Cycle, Female, Fumarate Hydratase, Humans, Leiomyoma, Neoplasms, Paraganglioma, Succinate Dehydrogenase, Tumor Cells, Cultured, Germ-Line Mutation, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.